Novo Nordisk aims to learn more about obesity risk through new collaboration

Digni Health and the Danish pharmaceutical firm have established a pilot project to find out what personal factors might affect a person’s obesity risk.

Photo: Tidsvilde Stine/Ritzau Scanpix

In a new pilot project, Novo Nordisk and Digbi Health will investigate how genomic and microbiome-based tests can help prevent obesity, reports industry media Fierce Biotech.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs